Zimbabwe rolls out lenacapavir for HIV prevention.
Zimbabwe has begun administering lenacapavir, a long-acting injectable HIV prevention drug administered twice a year, targeting more than 46,000 people at high risk across 24 sites with funding from the U.S. and the Global Fund.
